Yunnan Baiyao Group To Revisit Fundraising
This article was originally published in PharmAsia News
Executive Summary
Yunnan Baiyao Group, a leading TCM company in China, has unconfirmed plans to try again to get private financing, according to industry insiders. Sources disclose that the firm has been experiencing business slowdown since 2007 due to production capacity shortfalls while its relocation project requires a large investment. The capital raised will be used to construct its new production park and fund-fixed assets. The manufacturing base, with a phase one investment of 1.08 billion yuan ($157 million), is designed to produce 14 formulations and has capacity to expand its current output five-fold to reach 10 billion yuan. It will introduce up-to-date pharmaceutical equipment from Germany to upgrade the production system's automation control level and efficiency. (Click here for more - Chinese Language)